Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares Issued
Ratios

Akebia Therapeutics (AKBA) Receivables - Other (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Receivables - Other for 10 consecutive years, with $500000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Other fell 75.12% to $500000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $500000.0 through Dec 2025, down 75.12% year-over-year, with the annual reading at $500000.0 for FY2025, 75.12% down from the prior year.
  • Receivables - Other for Q4 2025 was $500000.0 at Akebia Therapeutics, roughly flat from $500000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $56.6 million in Q2 2022, with the low at $417000.0 in Q1 2023.
  • Average Receivables - Other over 5 years is $6.4 million, with a median of $1.9 million recorded in 2021.
  • The sharpest move saw Receivables - Other tumbled 97.73% in 2021, then skyrocketed 2837.03% in 2022.
  • Over 5 years, Receivables - Other stood at $19.1 million in 2021, then crashed by 90.04% to $1.9 million in 2022, then surged by 75.33% to $3.3 million in 2023, then plummeted by 39.69% to $2.0 million in 2024, then crashed by 75.12% to $500000.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $500000.0, $500000.0, and $1.2 million for Q4 2025, Q2 2025, and Q1 2025 respectively.